Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | PPARD | Q03181 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9330888 | 1.00 | PPARG (0.62) | PPARGPPARDPPARAACHECYP3A4 | |
| SCHEMBL5465903 | 1.00 | PPARG (0.62) | PPARGPPARDPPARAACHECYP3A4 | |
| Hydrochloric Acid SCHEMBL11337249 | 0.98 | PPARG (0.60) | PPARGPPARDPPARAACHECYP3A4 | |
| SCHEMBL9524187 | 0.86 | GAA (0.49) | PPARGPPARDPPARAACHECYP3A4 | |
| SCHEMBL7436426 | 0.86 | PPARG (0.54) | PPARGPPARDPPARAACHECYP3A4 | |
| SCHEMBL8372401 | 0.86 | TSHR (0.68) | ACHECYP3A4TSHRNFKB1NPSR1 | |
| SCHEMBL14032377 | 0.85 | ACHE (0.51) | PPARGPPARDPPARAACHENFKB1 | |
| SCHEMBL18793774 | 0.84 | CYP3A4 (0.45) | PPARGPPARDPPARAACHECYP3A4 | |
| SCHEMBL15517309 | 0.84 | PDE2A (0.47) | PPARGPPARDPPARAACHECYP3A4 | |
| SCHEMBL15517307 | 0.84 | PDE2A (0.47) | PPARGPPARDPPARAACHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024340-A1 | Compositions and Methods For Treating Migraine | FISH & RICHARDSON P.C. | 2024-01-25 | — | — | US | disclosed |
| EP-4251181-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | Wesana Health Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20190106380-A1 | Aromatic Derivatives As Anti-Malarial | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-11 | — | — | US | disclosed |
| CN-106243000-B | A kind of Valinamide carbamate derivatives of base containing propynyloxy and application | 南开大学 | 2017-12-05 | — | — | CN | disclosed |
| EP-2888240-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | Alios Biopharma, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031784-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | ALIOS BIOPHARMA, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| CN-1989113-B | Quinazoline derivatives | NOVARTIS AG | 2011-02-16 | — | — | CN | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| CN-1989113-A | Quinazoline derivatives | NOVARTIS AG (CH) | 2007-06-27 | — | — | CN | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| US-5281605-A | Pharmaceuticals | SANDOZ LTD. (CH) | 1994-01-25 | — | — | US | disclosed |
| EP-0258191-B1 | XANTHINE DERIVATIVES | SANDOZ AG (CH) | 1992-05-27 | — | — | EP | disclosed |
| WO-1988005775-A1 | NOVEL XANTHINE DERIVATIVES | SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) | 1988-08-11 | — | — | WO | disclosed |
| EP-0258191-A1 | Xanthine derivatives | SANDOZ AG (CH) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106380-A1 | Aromatic Derivatives As Anti-Malarial | TYR, CYP3A43, H1-3 | PPARG 2605/4885PPARD 2169/4885PPARA 3255/4885 |
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | PPARG 1234/4885PPARD 765/4885PPARA 2588/4885 |
| US-20240024340-A1 | Compositions and Methods For Treating Migraine | ACHE, GSK3B, HTR1B | PPARG 2732/4885PPARD 2949/4885PPARA 3694/4885 |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | ADRA2C, ADRB2, ADRB3 | PPARG 579/4885PPARD 473/4885PPARA 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.